Reward Emotion Learning and Ketamine Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-25

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described. Work in the animal literature and research in humans is suggestive of specific effects on anhedonia and memory reconsolidation. In this study the investigators will further explore the effects of ketamine on learning and memory as well as measuring the associated changes at neural level in a sample of healthy volunteers. Participants will be assigned to receive ketamine or placebo and complete a set of tasks which will allow the investigators to quantify the effect of ketamine on learning about reward and punishment and memory for learned reward associations 24 hours after ketamine infusion. This study will help the investigators to understand the basis of ketamine's antidepressant effects and aid the development of new treatments for depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glutamate Emotion Memory Study

NCT05809609

Treatment Resistant Depression Depression Major Depressive Disorder

RECRUITING NA

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

NCT05327699

Major Depressive Disorder

RECRUITING EARLY_PHASE1

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

NCT02610712

Depressive Disorder, Treatment-Resistant

UNKNOWN PHASE4

Ketamine's Actions on Rumination Mechanisms as an Antidepressant

NCT04656886

Remission in Depression

COMPLETED NA

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782

Major Depressive Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Major Depressive Disorder Treatment Resistant Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be assigned to receive either ketamine or placebo. Ketamine is not being administered for treatment purposes, the purpose is to understand the mechanisms underpinning its effects.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

All members of the study team will be blinded to the condition a participant is allocated to with the exception of the team member responsible for administering the drug/placebo.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketamine

Participants in this arm will receive a single intravenous, antidepressant dose of ketamine hydrochloride (0.5mg/kg)

Group Type EXPERIMENTAL

Ketamine Hydrochloride

Intervention Type DRUG

Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.

Placebo

Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride).

Group Type PLACEBO_COMPARATOR

No intervention (placebo)

Intervention Type OTHER

Placebo injection (0.9% sodium chloride)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine Hydrochloride

Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.

Intervention Type DRUG

No intervention (placebo)

Placebo injection (0.9% sodium chloride)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between 18 and 30
* Participant is willing and able to give informed consent for participation in the study
* Sufficient knowledge of English language to understand and complete study tasks
* Willingness to refrain from driving, cycling, or operating heavy machinery, until the following morning or a restful sleep has occurred, whichever is later.
* Willingness to refrain from signing legal documents within 7 days after the infusion visit.
* Willingness to refrain from drinking alcohol for 3 days before the infusion visit and one day before any of the other visits throughout the study

Exclusion Criteria

* Any current or past DSM-V significant psychiatric disorder including any psychotic, mood and anxiety and borderline personality disorders
* History of, or current medical conditions which in the opinion of the investigator may interfere with the safety of the participant or the scientific integrity of the study, including epilepsy/seizures, brain injury, hepatic or renal disease, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, neurological conditions
* First-degree relative with a diagnosis of schizophrenia-spectrum or other psychotic disorder, or bipolar disorder
* History of unexplained hallucinations or impulse control problems (e.g. pathological gambling)
* Current or past history of heart rhythm disorders
* Clinically significant hypertension
* Increased intraocular pressure/glaucoma
* Current pregnancy (as determined by urine pregnancy test taken during Screening and Infusion Visits) or breastfeeding
* Clinically significant abnormal values for clinical chemistry (e.g. liver function tests), urine drug screen, blood pressure measurement and ECG. A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
* Current or previous intake (last three months) of any medication that has a significant potential to affect mental functioning (e.g. benzodiazepines, antidepressants, neuroleptics etc.)
* Any intake of recreational drugs in the last 3 months (e.g. marijuana, ecstasy etc.)
* Lifetime recreational use of ketamine or phencyclidine
* Regular alcohol consumption of more than 14 units a week or excessive alcohol consumption up to three days before any of the in-person study visits
* Inability to abstain from alcohol for more than 1 week
* Regular smoker (\> 5 cigarettes per day)
* Excessive caffeine user (\> 6 caffeinated drinks per day)
* History of recurrent rashes or history of allergic reactions to relevant substances (ketamine treatment, placebo treatment)
* Previous participation in a study using the same or similar tasks
* Current participation in another study or participation in similar study within the last 6 months
* Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator
* Claustrophobia
* Any implants (including dental implants) or pacemaker
* Tattoos above the chest
* Any other MRI contraindications outlined in FMRIB 7 Tesla scanning safety form

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes